Phosphorylation of p53: A novel pathway for p53 inactivation in human t- cell lymphotropic virus type 1-transformed cells

Journal of Virology

Volumn 72, Issue 8, 1998, Pages 6348-6355

  Pise Masison, Cynthia A ^a   Radonovich, Michael ^a   Sakaguchi, Kazuyasu ^b   Appella, Ettore ^b   Brady, John N ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CARCINOGENICITY; CELL TRANSFORMATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; STRUCTURE ACTIVITY RELATION; VIRUS TRANSCRIPTION;

EID: 0031903407     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.8.6348-6355.1998     Document Type: Article

References (53)

1. Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. Giordano, A. S. Levine, and K. Kelly. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:1175-1184.
2. Baker, S. J., S. Markowitz, E. R. Fearon, J. K. Willson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915.
3. Cereseto, A., F. Diella, J. C. Mulloy, A. Cara, P. Michieli, R. Grassmann, G. Franchini, and M. E. Klotman. 1996. p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. Blood 88:1551-1560.
4. Chen, P. L., Y. M. Chen, R. Bookstein, and W. H. Lee. 1990. Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1580.
5. Diller, L., J. Kassel, C. E. Nelson, M. A. Gryka, G. Litwak, M. Gebhardt, B. Bressac, M. Ozturk, S. J. Baker, and B. Vogelstein. 1990. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:5772-5781.
6. Dutta, A., S. M. Ruppert, J. C. Aster, and E. Winchester. 1993. Inhibition of DNA replication factor RPA by p53. Nature 365:79-82.
7. El-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
8. Fiscella, M., S. J. Ullrich, N. Zambrano, M. T. Shields, D. Lin, S. P. Lees-Miller, C. W. Anderson, W. E. Mercer, and E. Appella. 1993. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8:1519-1528.
9. Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866-2871.
10. Gartenhaus, R. B., and P. Wang. 1995. Functional inactivation of wild-type p53 protein correlates with loss of IL-2 dependence in HTLV-I transformed human T lymphocytes. Leukemia 9:2082-2086.
11. Gessain, A., F. Barin, J. C. Vernant, O. Gout, L. Maurs, A. Calender, and G. de The. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2:407-410.
12. Gottlieb, T. M., and M. Oren. 1996. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287:77-102.
13. Gu, W., X. Shi, and R. G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature 387:819-823.
14. He, Z., B. T. Brinton, J. Greenblatt, J. A. Hassell, and C. J. Ingels. 1993. The transactivator proteins VP16 and GAL4 bind replication factor A. Cell 73:1223-1232.
15. Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig, B. Smith-Sorensen, R. Montesano, and C. C. Harris. 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:3551-3555.
16. Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875-886.
17. Ijichi, S., T. Matsuda, I. Maruyama, T. Izumihara, K. Kojima, T. Niimura, Y. Maruyama, S. Sonoda, A. Yoshida, and M. Osame. 1990. Arthritis in a human T lymphotropic virus type I (HTLV-I) carrier. Ann. Rheum. Dis. 49:718-721.
18. Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
19. LaGrenade, L., B. Hanchard, V. Fletcher, B. Cranston, and W. Blattner. 1990. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 336:1345-1347.
20. Lees-Miller, S. P., K. Sakaguchi, S. J. Ullrich, E. Appella, and C. W. Anderson. 1992. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol. 12:5041-5049.
21. Leveillard, T., L. Andera, N. Bissonnette, L. Schaeffer, L. Bracco, J. M. Egly, and B. Wasylyk. 1996. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 15:1615-1624.
22. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
23. Li, R., and M. R. Botchan. 1993. The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication. Cell 73:1207-1221.
24. Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingstnn. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827.
25. Lin, J., J. Chen, B. Elenbaas, and A. J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and ehe adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1235-1246.
26. Lu, H., and A. J. Levine. 1995. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92:5154-5158.
27. Mayr, G. A., M. Reed, P. Wang, Y. Wang, J. F. Schweds, and P. Tegtmeyer. 1995. Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation. Cancer Res. 55:2410-2417.
28. Mercer, W. E., M. T. Shields, M. Amin, G. J. Sauve, E. Appella, J. W. Romano, and S. J. Ullrich. 1990. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl. Acad. Sci. USA 87:6166-6170.
29. Milne, D. M., L. E. Campbell, D. G. Campbell, and D. W. Meek. 1995. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J. Biol. Chem. 270:5511-5518.
30. Milne, D. M., R. H. Palmer, D. G. Campbell, and D. W. Meek. 1992. Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. Oncogene 7:1361-1369.
31. Milner, J. 1991. A conformation hypothesis for the suppressor and promoter functions of p53 in cell growth control and in cancer. Proc. R. Soc. Lond. Ser. B 245:139-145.
32. Nagai, H., T. Kinoshita, J. Imamura, Y. Murakami, K. Hayashi, K. Mukai, S. Ikeda, K. Tobinai, H. Saito, and M. Shimoyama. 1991. Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn. J. Cancer Res. 82:1421-1427.
33. O'Connor, D. J., E. W. Lam, S. Griffin, S. Zhong, L. C. Leighton, S. A. Burbidge, and X. Lu. 1995. Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J. 14:6184-6192.
34. Osame, M., K. Usuku, S. Izumo, N. Ijichi, H. Amitani, A. Igata, M. Matsumoto, and M. Tara. 1986. HTLV-I associated myelopathy, a new clinical entity. Lancet 1:1031-1032. (Letter.)
35. Pietenpol, J. A., T. Tokino, S. Thiagalingam, W. S. El-Deiry, K. W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91:1998-2002.
36. Pise-Masison, C. A., K.-S. Choi, M. Radonovich, J. Dittmer, S.-J. Kim, and J. N. Brady. 1998. Inhibition of p53 transactivation function by the human T-cell leukemia virus type 1 Tax protein. J. Virol. 72:1165-1170.
37. Poiesz, B. J., F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C. Gallo. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 77:7415-7419.
38. Reid, R. L., P. F. Lindholm, A. Mireskandari, J. Dittmer, and J. N. Brady. 1993. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene 8:3029-3036.
39. Sakaguchi, K., H. Sakamoto, M. S. Lewis, C. W. Anderson, J. W. Erickson, E. Appella, and D. Xie. 1997. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36:10117-10124.
40. Sakashita, A., T. Hattori, C. W. Miller, H. Suzushima, N. Asou, K. Takatsuki, and H. P. Koeffier. 1992. Mutations of the p53 gene in adult T-cell leukemia. Blood 79:477-180.
41. Sasaki, K., I. Morooka, H. Inomata, N. Kashio, T. Akamine, and M. Osame. 1989. Retinal vasculitis in human T-lymphotropic virus type I associated myelopathy. Br. J. Ophthalmol. 73:812-815.
42. Shieh, S., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induce phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
43. Siliciano, J. D., C. E. Canman, Y. Taya, K. Sakaguchi, E. Appella, and M. B. Kastan. 1997. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:3471-3481.
44. Steegenga, W. T., A. J. van der Eb, and A. G. Jochemsen. 1996. How phosphorylation regulates the activity of p53. J. Mol. Biol. 263:103-113.
45. Thut, C. J., J. L. Chen, R. Klemm, and R. Tjian. 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267:100-104.
46. Truant, R., J. Antunovic, J. Greenblatt, C. Prives, and J. A. Cromlish. 1995. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J. Virol. 69:1851-1859.
47. Ullrich, S. J., C. W. Anderson, W. E. Mercer, and E. Appella. 1992. The p53 tumor suppressor protein, a modulator of cell proliferation. J. Biol. Chem. 267:15259-15262.
48. Ullrich, S. J., K. Sakaguchi, S. P. Lees-Miller, M. Fiscella, W. E. Mercer, C. W. Anderson, and E. Appella. 1993. Phosphorylation at Ser-15 and Ser392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. Proc. Natl. Acad. Sci. USA 90:5954-5958.
49. Wang, X. W., H. Yen, L. Schaeffer, R. Roy, V. Moncollin, J. M. Egly, Z. Wang, E. C. Freidberg, M. K. Evans, and B. G. Taffe. 1995. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet. 10:188-195.
50. Xiao, H., A. Pearson, B. Coulombe, R. Truant, S. Zhang, J. L. Regier, S. J. Triezenberg, D. Reinberg, O. Flores, and C. J. Ingles. 1994. Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol. Cell. Biol. 14:7013-7024.
51. Xiao, H., A. Pearson, B. Coulombe, R. Truant, S. Zhang, J. L. Regier, S. J. Triezenberg, D. Reinberg, O. Flores, C. J. Ingles, and J. Greenblatt. 1994. Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and P53. Mol. Cell. Biol. 14:7013-7024.
52. Yoshida, M., M. Seiki, K. Yamaguchi, and K. Takatsuki. 1984. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc. Natl. Acad. Sci. USA 81:2534-2537.
53. Zhou, Q., P. M. Lieberman, T. G. Boyer, and A. J. Berk. 1992. Holo-TFIID supports transcriptional stimulation by diverse activators and from a TATA-less promoter. Genes Dev. 6:1964-1974.